Prevalence, mechanisms, and management of cancer-related cognitive impairment (2014)

Peer-Reviewed Study · Janelsins MC, Kesler SR, Ahles TA, Morrow GR · February 2014

Janelsins MC et al., 2014-02: Review of cancer-related cognitive impairment in patients receiving adjuvant chemotherapy. It states that up to 75% of patients report some form of impairment during treatment, and in the same sentence puts persistent impairment at up to 35% years after treatment.

up to 75% of patients report some form of CRCI during treatment, and CRCI is still present in up to 35% of patients many years following completion of treatment

Abstract

Janelsins MC et al., 2014-02: Review of cancer-related cognitive impairment in patients receiving adjuvant chemotherapy. It states that up to 75% of patients report some form of impairment during treatment, and in the same sentence puts persistent impairment at up to 35% years after treatment. This is the origin of the book's 75% number, and it refers to SELF-REPORTED cognitive problems DURING treatment, not measured cognitive impairment. Comparator: none (review). Funder: PMC deposit is an NIH author manuscript (NIHPA); specific grant and COI statements were not in the text captured. The same abstract also says problems can be detected in up to 30% of patients BEFORE chemotherapy, which is the key confound for attributing the deficit to the drugs. Study type: review.